Candel Therapeutics, Inc.
CADL
Rank in Stocks
#12811
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in... Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Share Price
$5.40
Last synced: 2026-11-17
Market Cap
$417.88M
Change (1 day)
-7.06%
Change (1 year)
22.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Candel Therapeutics, Inc. (CADL)
Category
Healthcare
Operating Margin for Candel Therapeutics, Inc. (CADL)
Operating Margin as of November 2026 TTM: 0.00%
According to Candel Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Candel Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -27,777.60% | 34.97% |
| 2021 | -20,580.80% | 86.29% |
| 2020 | -11,048.00% | 52.82% |
| 2019 | -7,229.60% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | - |
US
|
|
| 33.87% | - |
US
|
|
| -116.04% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Candel Therapeutics, Inc.'s operating margin
What was Candel Therapeutics, Inc.'s operating margin in 2025?
In 2025, Candel Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Candel Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Candel Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2022 (-27,777.60%).
How does Candel Therapeutics, Inc.'s operating margin compare with similar companies?
Candel Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.